Ascletis Pharma, Inc. (HK:1672) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ascletis Pharma’s new weight loss drug candidate, ASC47, combined with semaglutide, has shown promising results in preclinical trials, achieving more significant weight reduction and muscle preservation compared to semaglutide alone. The combination treatment demonstrated a 36.2% total body weight reduction in obese mice, outperforming the 23.1% reduction observed with semaglutide monotherapy. With ongoing Phase I trials in Australia showing good tolerability, this development could be a significant advancement in obesity treatment.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.